Two different jobs in the same joint

Both ChondroFiller® and Arthrosamid® are injected into the joint in an outpatient setting — so it is entirely reasonable to ask whether choosing between them is simply a matter of preference or price. It is not. They address different anatomical problems and should not be treated as alternatives competing for the same role.

ChondroFiller injection delivers an acellular Type I collagen scaffold directly onto the worn articular surfaces at the bone ends. Its purpose is to support structural repair — providing a matrix that recruits the body's own progenitor cells to promote cartilage-like tissue formation where the cartilage surface has degraded.

Arthrosamid® is a 2.5% cross-linked polyacrylamide hydrogel that adheres to the synovial membrane — the soft-tissue lining of the joint cavity. It does not act on the cartilage surface at all. Its role is mechanical buffering and pain modulation at the synovial level.

A useful shorthand: ChondroFiller injection is closer to repairing worn tyre tread; Arthrosamid® is closer to fitting a new suspension cushion. Both matter, but they solve different problems. The practical decision question is therefore not which product is superior — it is what the joint actually needs: structural repair, symptom control, or, in some advanced cases, both simultaneously.

How ChondroFiller injection works on bone-end cartilage

The collagen in ChondroFiller injection is not a painkiller, a filler, or a lubricant — and understanding that distinction clarifies why it behaves differently from other joint injections.

ChondroFiller® is a CE-marked Class III medical device manufactured by Meidrix Biomedicals in Germany. The active material is an acellular, murine-derived Type I collagen solution that, once placed inside the joint, gels in situ directly over the worn articular surfaces at the bone ends. Because it contains no cells of its own, its therapeutic action depends entirely on what the body does next.

Matrix-induced chondrogenesis: what happens inside the joint

The gelled collagen matrix acts as a homing signal and physical scaffold simultaneously. Chondrogenic progenitor cells — the body's cartilage-building precursor cells, drawn from the synovium and subchondral bone — migrate into the matrix and begin to differentiate. This process is known as matrix-induced chondrogenesis, and it is what supports the body's own repair response rather than introducing externally grown tissue.

Delivery and patient access

At London Cartilage Clinic on Harley Street, ChondroFiller injection is administered as an ultrasound-guided outpatient procedure — no general anaesthetic, no operating theatre. The collagen is deposited in a fluid joint environment, coating the worn bone-end surface from the top down. This additive approach means the procedure does the protective work itself, without requiring large volumes of new tissue to grow beforehand. There is no upper age limit and no defect-size restriction; the pathway is applicable to Kellgren-Lawrence Grade IV 'bone-on-bone' joints where surgery is not appropriate.

The injection is suitable across multiple joints: knee, hip, ankle, shoulder, elbow, wrist, thumb, small hand joints, and TMJ — provided joint mechanics are stable.

How Arthrosamid works on the synovial membrane

Unlike ChondroFiller injection, Arthrosamid® does not target the cartilage surface at all. Its site of action is the synovial membrane — the soft-tissue lining of the joint cavity — and its mechanism is physical rather than regenerative.

The product consists of 2.5% cross-linked polyacrylamide in 97.5% non-pyrogenic water. Critically, the polyacrylamide network is non-degradable and non-resorbable: once injected, it is intended to remain in the joint permanently. After the 6 mL injection, the hydrogel adheres to the synovial membrane and, over time, infiltrating synovial lining cells incorporate into its structure, forming a de novo tissue layer at the membrane surface (Henriksen et al. 2018; Tnibar et al. 2017). The result is a persistent mechanical buffer that may reduce the load and inflammatory signals transmitted through the joint — but it does not lay down cartilage matrix or rebuild the articular surface.

Maulana, Cole and Lee (2022) documented a reduction in patellofemoral bone marrow lesions following a single iPAAG injection. This finding is clinically interesting, though it is consistent with load redistribution rather than structural cartilage repair, and should not be interpreted as evidence that Arthrosamid® regenerates tissue.

On safety, published adverse event rates for inflammatory effusion may underestimate the true clinical incidence: studies measured 'sensation of distension' — a subjective patient-reported outcome — rather than confirming effusion through examination or imaging. Patients considering Arthrosamid® should discuss this limitation with their clinician before proceeding.

What the clinical evidence shows

The strongest single data point for the ChondroFiller injection pathway comes from Jerosch et al.'s prospective post-market clinical follow-up (PMCF) study: a mean IKDC score improvement of 32.4 points, sustained — and slightly increased — at three years of follow-up, reaching a functional score of 80. The minimum clinically important difference (MCID) for the IKDC is 16.7 points, meaning a 30-point gain broadly corresponds to moving from significant daily limitation to near-normal joint function. Across four independent studies, ChondroFiller injection produced consistent improvements of approximately 30 IKDC points. Structural repair, measured via MOCART scores, reached 81.6–84.3 in European cohorts — reflecting more than 80% defect filling with good native cartilage integration.

Against established surgical benchmarks, those figures are comparable to ACI/MACI (approximately 30–35 IKDC points) delivered as a single outpatient procedure. Published complication rates sit at approximately 0% versus up to 17% for cell-based two-stage procedures, and reoperation rates of 3–8% versus up to 37%. Structural outcomes also exceed the fibrocartilage ceiling of microfracture, where repair tissue quality is inherently limited.

For Arthrosamid®, the evidence addresses a different clinical question. Bliddal et al.'s 52-week prospective study confirmed significant improvement in knee OA symptoms, with a 12-month open-label follow-up (J Orthop Surg Res 2024;19:274) supporting sustained effectiveness and safety. Maulana, Cole and Lee (2022) documented reduced patellofemoral bone marrow lesions, noted in the previous section.

Evidence gaps

No head-to-head randomised controlled trial has compared ChondroFiller injection directly with Arthrosamid®. CFI injection outcome data derives primarily from manufacturer-sponsored PMCF studies; Arthrosamid® trials are open-label. The two products were also tested in different patient populations — focal cartilage defects versus diffuse OA — so placing their outcome figures side by side as equivalent comparisons would be misleading. These limitations are worth knowing; they do not invalidate the data, but they do mean individual suitability requires clinical assessment rather than a direct numbers comparison.

Which pathway fits which patient

The decision hinges on what the joint actually needs structurally — not only what is causing pain, and not on which product sounds more advanced. Three clinical profiles map to three distinct pathways.

ChondroFiller injection pathway — structural repair

Patients with focal Grade III or IV cartilage defects, and those with diffuse advanced wear including Kellgren-Lawrence Grade IV 'bone-on-bone' joints where surgery is not appropriate, are typically best served by the ChondroFiller injection pathway. No upper age ceiling and no defect-size restriction apply; the ultrasound-guided outpatient procedure coats the worn articular bone-end surfaces directly, supporting the body's own repair processes through matrix-induced chondrogenesis. Stable joint mechanics — no untreated ligament instability or significant malalignment — are required.

Arthrosamid pathway — synovial buffering

Where the primary clinical need is pain modulation and mechanical cushioning at the synovial level — particularly moderate-to-advanced OA in which the damage is diffuse across the joint rather than focal — Arthrosamid addresses a different problem entirely. Its action is at the synovial membrane, not on the cartilage surface; it provides no regenerative scaffold function. For patients whose joints sit beyond the regenerative indication, its role is to reduce load transmission and inflammatory signalling at the membrane.

Combined protocol — addressing both dimensions simultaneously

For KL Grade III/IV joints where both the articular surfaces and the synovial environment are involved, a dual-injection protocol delivers ChondroFiller injection (2.3 mL on the bone ends) and Arthrosamid (6 mL on the synovium) in a single outpatient visit. These two products are doing different jobs in different tissues; combining them targets the structural and synovial dimensions at the same time rather than doubling up on one mechanism. Guide cost, as confirmed by the treating clinic, is approximately £6,000.

In the most advanced cases, autologous mesenchymal stem cells may be added to the dual protocol — a triple-therapy approach intended to provide structural scaffolding, synovial buffering, and additional cellular signalling simultaneously.

Which profile applies to a specific joint requires clinical assessment; none of the above should be read as a personal recommendation.

Getting an assessment at the London Cartilage Clinic

The central point of this article is also the central question of the assessment: is the joint's primary problem a worn articular surface, a distressed synovial environment, or both? ChondroFiller injection and Arthrosamid® are not interchangeable options — they operate on different tissues, through different mechanisms, and suit different clinical profiles. Matching the right product to the right problem is where the outcome is won or lost.

Technique matters as much as product selection. At London Cartilage Clinic on Harley Street — the UK certified delivery centre for ChondroFiller injection — Professor Paul Y. F. Lee leads the service. Precision in delivery, and experience in reading which pathway fits which joint, are variables a clinic assessment can weigh in a way that no comparison article can.

Patients who want to explore whether the ChondroFiller injection pathway, Arthrosamid, or a combined protocol is appropriate for their joint can book a clinical assessment at londoncartilage.com.